We are live on ! Find out more
GOSS icon

Gossamer Bio

164 hedge funds and large institutions have $474M invested in Gossamer Bio in 2025 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 49 increasing their positions, 44 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,529% more call options, than puts

Call options by funds: $26.8M | Put options by funds: $738K

300% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 14

117% more capital invested

Capital invested by funds: $218M → $474M (+$256M)

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

33% more funds holding

Funds holding: 123164 (+41)

11% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 44

1.41% more ownership

Funds ownership: 77.79%79.21% (+1.4%)

Holders
164
Holders Change
+41
Holders Change %
+33.33%
% of All Funds
2.15%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
56
Increased
49
Reduced
44
Closed
14
Calls
$26.8M
Puts
$738K
Net Calls
+$26M
Net Calls Change
+$21.9M
Name Holding Trade Value Shares
Change
Change in
Stake
NMC
1
NEA Management Company
Maryland
$47.6M
OCA
2
Octagon Capital Advisors
New York
$44.8M -$2.87M -1,300,000 -7%
BlackRock
3
BlackRock
New York
$36.4M +$3.75M +1,703,458 +14%
Vanguard Group
4
Vanguard Group
Pennsylvania
$31.6M +$1.32M +598,981 +5%
AVM
5
Arch Venture Management
Illinois
$21.2M
SB
6
Samsara BioCapital
California
$16.1M
PAI
7
Palo Alto Investors
California
$14.4M -$605K -274,664 -5%
SL
8
Siren LLC
Connecticut
$13.7M
6CM
9
683 Capital Management
New York
$13.3M -$2.82M -1,280,800 -20%
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$13.2M -$4.7M -2,133,053 -30%
HA
11
HHLR Advisors
Cayman Islands
$13.1M
SCM
12
Silverarc Capital Management
Massachusetts
$12.6M -$810K -367,700 -7%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$12.3M +$296K +134,451 +3%
Fidelity Investments
14
Fidelity Investments
Massachusetts
$10.7M -$7.12M -3,229,979 -44%
State Street
15
State Street
Massachusetts
$10.2M +$3.09M +1,402,261 +57%
PA
16
Perceptive Advisors
New York
$10M +$8.4M +3,812,797 New
Millennium Management
17
Millennium Management
New York
$9.52M +$6.88M +3,123,081 +629%
RSCM
18
Rock Springs Capital Management
Maryland
$8.59M
Renaissance Technologies
19
Renaissance Technologies
New York
$7.84M +$546K +247,894 +9%
Bank of America
20
Bank of America
North Carolina
$7.58M +$6.2M +2,814,824 +4,196%
UBS Group
21
UBS Group
Switzerland
$7.29M +$5.42M +2,457,304 +786%
OM
22
Opaleye Management
Massachusetts
$7.17M -$1.81M -820,000 -23%
Two Sigma Investments
23
Two Sigma Investments
New York
$6.02M +$1.19M +542,124 +31%
Citadel Advisors
24
Citadel Advisors
Florida
$6.01M +$3.34M +1,516,655 +198%
Alyeska Investment Group
25
Alyeska Investment Group
Illinois
$5.02M -$5.62M -2,550,000 -57%

GOSS Hedge Fund Activity: Q3 2025 in Review

164 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q3 2025, worth a combined $474M — up 117% from $218M a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new GOSS positions and 14 closed out — a net gain of 42 holders — while 49 added to existing stakes and 44 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $8.4M. The largest seller was Corient Private Wealth, cutting an estimated $8.1M.

  • 164 institutional investors held Gossamer Bio (GOSS) as of Q3 2025, up from 123 in Q2 2025.
  • Funds reported $474M of Gossamer Bio stock for Q3 2025, up 117% quarter-over-quarter.
  • 56 funds opened new Gossamer Bio positions in Q3 2025 and 14 closed out, a net change of +42 holders.
  • The largest Gossamer Bio buyer in Q3 2025 was Perceptive Advisors, an estimated $8.4M added.
  • The largest Gossamer Bio seller in Q3 2025 was Corient Private Wealth, an estimated $8.1M sold.

Based on aggregated 13F filings for Q3 2025.